Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2011-06-28 Regulatory Filings
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates that the company, Insmed Incorporated, is announcing its addition to the Russell 3000 Index via a press release attached as an exhibit. There is no substantive financial data, detailed financial statements, or comprehensive report content. The document is short (2690 characters) and primarily serves as an announcement of an event and a press release attachment. It does not fit into categories like Annual Report, Earnings Release, or Interim Report. It is not a certification or officer attestation. Given the nature of the filing and the content, this is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2011-06-28 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions a press release about positive clinical trial data attached as an exhibit, but the main content is a brief announcement rather than a detailed report. The document length is only 2830 characters, which is quite short and consistent with an announcement rather than a full report. There are no financial statements or detailed financial data included. The document explicitly states that the press release is attached as an exhibit and is not considered "filed" for certain regulatory purposes, indicating this is an announcement of an event rather than a full report. Therefore, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-06-13 English
8-K Filing
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 18, 2011, reporting the submission of matters to a vote of security holders at the company's 2011 annual meeting. It details the voting results on various proposals including election of directors, ratification of auditors, amendment of stock incentive plan, and advisory votes on executive compensation. The content is focused on official results from shareholder votes at the annual meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is 5950 characters, sufficient to contain detailed voting results rather than just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2011-05-23 English
8-K Filing
Call Transcript Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2011, by Insmed Incorporated. It specifically states that the company held a conference call to discuss first quarter earnings for 2011 and that a transcript of this call is attached as Exhibit 99.1. The text emphasizes the conference call and the transcript, which is typical for earnings call transcripts. There is no detailed financial data or comprehensive report content, only a reference to the transcript of the call. Therefore, this document is best classified as a Call Transcript (CT). The document length is 3678 characters, which is consistent with a transcript or a report containing a transcript. Confidence is high due to explicit mention of the transcript and the nature of the filing.
2011-05-11 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release regarding financial results for the quarter ended March 31, 2011, and that the press release is attached as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is short (2598 characters), and it primarily serves as an announcement of the earnings release rather than the earnings release itself. According to the rules, initial announcements of quarterly financial results are classified as Earnings Release (ER). Since the document includes the press release announcing quarterly results, the correct classification is ER with high confidence.
2011-05-10 English
10-Q Filing
Interim / Quarterly Report Q1 2011
2011-05-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.